"CD28 Antigens" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Costimulatory T-LYMPHOCYTE receptors that have specificity for CD80 ANTIGEN and CD86 ANTIGEN. Activation of this receptor results in increased T-cell proliferation, cytokine production and promotion of T-cell survival.
| Descriptor ID |
D018106
|
| MeSH Number(s) |
D12.776.543.750.705.222.500 D23.050.301.264.894.128 D23.101.100.894.128
|
| Concept/Terms |
CD28 Antigens- CD28 Antigens
- TP44 Receptor
- Receptor, TP44
- T-Cell-Specific Surface Glycoprotein CD28
- T Cell Specific Surface Glycoprotein CD28
- CD28 Antigen
- Antigen, CD28
- Antigens, CD28
|
Below are MeSH descriptors whose meaning is more general than "CD28 Antigens".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Costimulatory and Inhibitory T-Cell Receptors [D12.776.543.750.705.222]
- CD28 Antigens [D12.776.543.750.705.222.500]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
- CD28 Antigens [D23.050.301.264.894.128]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
- CD28 Antigens [D23.101.100.894.128]
Below are MeSH descriptors whose meaning is more specific than "CD28 Antigens".
This graph shows the total number of publications written about "CD28 Antigens" by people in this website by year, and whether "CD28 Antigens" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 4 | 0 | 4 |
| 1995 | 3 | 1 | 4 |
| 1996 | 6 | 1 | 7 |
| 1997 | 6 | 2 | 8 |
| 1998 | 3 | 2 | 5 |
| 1999 | 2 | 2 | 4 |
| 2000 | 1 | 3 | 4 |
| 2001 | 1 | 3 | 4 |
| 2002 | 2 | 1 | 3 |
| 2003 | 3 | 3 | 6 |
| 2004 | 4 | 1 | 5 |
| 2005 | 1 | 5 | 6 |
| 2006 | 6 | 2 | 8 |
| 2007 | 1 | 3 | 4 |
| 2008 | 2 | 1 | 3 |
| 2009 | 3 | 2 | 5 |
| 2010 | 0 | 2 | 2 |
| 2011 | 2 | 5 | 7 |
| 2012 | 2 | 6 | 8 |
| 2013 | 1 | 2 | 3 |
| 2014 | 0 | 3 | 3 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 2 | 3 |
| 2017 | 2 | 2 | 4 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 2 | 2 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD28 Antigens" by people in Profiles.
-
CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3?/ZAP70 Signaling Axis. Cancer Discov. 2024 Oct 04; 14(10):1879-1900.
-
Human platelet lysate enhances in vivo activity of CAR-Vd2 T cells by reducing cellular senescence and apoptosis. Cytotherapy. 2024 Aug; 26(8):858-868.
-
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7). Blood Cancer Discov. 2024 01 08; 5(1):21-33.
-
CAR T-cell Design-dependent Remodeling of the Brain Tumor Immune Microenvironment Modulates Tumor-associated Macrophages and Anti-glioma Activity. Cancer Res Commun. 2023 12 01; 3(12):2430-2446.
-
Longitudinal Analysis of the Phenotype, Transcriptional Profile, and Anatomic Location of Memory CD8 T Cell Subsets after Acute Viral Infection. J Virol. 2023 01 31; 97(1):e0155622.
-
Phenotypic frailty in people living with HIV is not correlated with age or immunosenescence. Int J STD AIDS. 2022 05; 33(6):597-603.
-
Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci Transl Med. 2021 11 17; 13(620):eabh0272.
-
CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies. J Hematol Oncol. 2021 02 16; 14(1):26.
-
CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma. Clin Cancer Res. 2021 01 15; 27(2):473-484.
-
Histone Deacetylase Inhibitors and IL21 Cooperate to Reprogram Human Effector CD8+ T Cells to Memory T Cells. Cancer Immunol Res. 2020 06; 8(6):794-805.